In this study, the mutual prodrugs approach successfully led to a more potent CD13 inhibition compared with both ubenimex and previously reported BC01, suggesting an advantage for selectively targeting cancer cells overexpressing CD13. The gene discussed is ANPEP; the disease is cancer.